Juan MD - Anavex Life Senior Development
| AVXL Stock | USD 9.11 0.09 1.00% |
Executive
Juan MD is Senior Development of Anavex Life Sciences
| Address | 630 5th Avenue, New York, NY, United States, 10111 |
| Phone | 844 689 3939 |
| Web | https://www.anavex.com |
Anavex Life Management Efficiency
The company has return on total asset (ROA) of (0.2043) % which means that it has lost $0.2043 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3003) %, meaning that it created substantial loss on money invested by shareholders. Anavex Life's management efficiency ratios could be used to measure how well Anavex Life manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.29. Return On Capital Employed is expected to rise to -0.43 this year. At this time, Anavex Life's Total Assets are quite stable compared to the past year. Total Current Assets is expected to rise to about 186.4 M this year, although the value of Other Assets will most likely fall to about 3.7 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Joseph MD | Biovie Inc | 64 | |
| Brian JD | Madrigal Pharmaceuticals | 62 | |
| Michael Zamloot | Cassava Sciences | N/A | |
| Joshua Esq | INmune Bio | N/A | |
| PharmD MBA | Madrigal Pharmaceuticals | N/A | |
| Dana Aftab | Exelixis | 60 | |
| Lindsay Burns | Cassava Sciences | N/A | |
| Kevin Smyth | Iovance Biotherapeutics | N/A | |
| Michael PharmD | Cassava Sciences | N/A | |
| Pablo MD | Kodiak Sciences | N/A | |
| Kianoush Motesharei | Madrigal Pharmaceuticals | ||
| JD Esq | Novavax | 53 | |
| Christopher Reading | Biovie Inc | 76 | |
| Friso Postma | BioXcel Therapeutics | N/A | |
| Bobby Horn | Cognition Therapeutics | N/A | |
| Clint Wallace | Madrigal Pharmaceuticals | N/A | |
| Laura Dillard | Exelixis | N/A | |
| Tracy Winton | Iovance Biotherapeutics | N/A | |
| Matthew Wiley | BioXcel Therapeutics | 52 | |
| Edward Chiang | Madrigal Pharmaceuticals | N/A | |
| Andrew Jones | Eyenovia | 53 | |
Management Performance
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.2 |
Anavex Life Sciences Leadership Team
Elected by the shareholders, the Anavex Life's board of directors comprises two types of representatives: Anavex Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Anavex. The board's role is to monitor Anavex Life's management team and ensure that shareholders' interests are well served. Anavex Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Anavex Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| CPA CPA, Principal Treasurer | ||
| David RPh, Senior Affairs | ||
| Juan MD, Senior Development | ||
| Stephan Toutain, Senior Vice President - Operations | ||
| Dr RPh, VP Affairs | ||
| Kun Jin, Head Biostatistics | ||
| Terrie Kellmeyer, Senior Development | ||
| MD MPH, Chief Officer | ||
| Walter MD, Chief Officer | ||
| MS MBA, Senior COO | ||
| Adebayo Laniyonu, Senior Development | ||
| CGA CPA, Principal Treasurer | ||
| Clint Tomlinson, VP Corporate | ||
| MBA MS, President, Chairman |
Anavex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Anavex Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.2 | ||||
| Current Valuation | 626.1 M | ||||
| Shares Outstanding | 84.8 M | ||||
| Shares Owned By Insiders | 3.04 % | ||||
| Shares Owned By Institutions | 32.06 % | ||||
| Number Of Shares Shorted | 18.31 M | ||||
| Price To Earning | (11.03) X | ||||
| Price To Book | 5.89 X | ||||
| EBITDA | (47.5 M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anavex Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anavex Life. If investors know Anavex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anavex Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.51) | Return On Assets (0.20) | Return On Equity (0.30) |
The market value of Anavex Life Sciences is measured differently than its book value, which is the value of Anavex that is recorded on the company's balance sheet. Investors also form their own opinion of Anavex Life's value that differs from its market value or its book value, called intrinsic value, which is Anavex Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anavex Life's market value can be influenced by many factors that don't directly affect Anavex Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anavex Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Anavex Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anavex Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.